| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Short Communication |
1 CNRS, Institut de Biologie de Lille (UMR8161), Institut Pasteur de Lille, 1 rue Calmette, BP447, 59021 Lille cedex, France
2 Free University of Brussels, Faculty of Medicine, Laboratory of Molecular Virology, Brussels, Belgium
3 INSERM-U412, ENS de Lyon, Lyon, France
4 Hôpital Erasme, Free University of Brussels, Brussels, Belgium
5 Laboratory of Virology, Centre Hospitalier Universitaire d'Amiens, Amiens, France
Correspondence
Ngoc Vu-Dac
ngoc.vu-dac{at}ibl.fr
Jean Dubuisson
jean.dubuisson{at}ibl.fr
The neutralizing activity of anti-hepatitis C virus (HCV) antibodies is attenuated by a factor present in human sera, which has been proposed to be high-density lipoproteins (HDLs). HDLs have also been shown to facilitate the entry of HCV pseudoparticles (HCVpp) into target cells. Here, the aim of the study was to determine whether HDL-mediated facilitation of HCVpp and infectious HCV (HCVcc) entry and attenuation of neutralization are two related phenomena. The data indicated that HDLs attenuate neutralization at a constant rate. In addition, as for HDL-mediated facilitation of HCVpp entry, attenuation of neutralization depended on the expression of the scavenger receptor BI (SR-BI) and its selective lipid-uptake function. Finally, kinetic experiments showed that HDL-mediated facilitation of HCVpp entry is more rapid than virus neutralization. Altogether, these observations indicate that HCV is exploiting the physiological activity of SR-BI for promoting its entry into target cells, which consequently also protects the virus against neutralizing antibodies.
This article has been cited by other articles:
|
|
 |
|
  J M Timpe and J A McKeating Hepatitis C virus entry: possible targets for therapy Gut, December 1, 2008; 57(12): 1728 - 1737. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Meertens, C. Bertaux, L. Cukierman, E. Cormier, D. Lavillette, F.-L. Cosset, and T. Dragic The Tight Junction Proteins Claudin-1, -6, and -9 Are Entry Cofactors for Hepatitis C Virus J. Virol., April 1, 2008; 82(7): 3555 - 3560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. von Hahn and C. M. Rice Hepatitis C Virus Entry J. Biol. Chem., February 15, 2008; 283(7): 3689 - 3693. [Full Text] [PDF]
|
|
|
|
|
|
M. Dreux, B. Boson, S. Ricard-Blum, J. Molle, D. Lavillette, B. Bartosch, E.-I. Pecheur, and F.-L. Cosset The Exchangeable Apolipoprotein ApoC-I Promotes Membrane Fusion of Hepatitis C Virus J. Biol. Chem., November 2, 2007; 282(44): 32357 - 32369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. X. Johansson, C. Voisset, A. W. Tarr, M. Aung, J. K. Ball, J. Dubuisson, and M. A. A. Persson Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus PNAS, October 9, 2007; 104(41): 16269 - 16274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Catanese, R. Graziani, T. von Hahn, M. Moreau, T. Huby, G. Paonessa, C. Santini, A. Luzzago, C. M. Rice, R. Cortese, et al. High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein J. Virol., August 1, 2007; 81(15): 8063 - 8071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Helle, A. Goffard, V. Morel, G. Duverlie, J. McKeating, Z.-Y. Keck, S. Foung, F. Penin, J. Dubuisson, and C. Voisset The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein J. Virol., August 1, 2007; 81(15): 8101 - 8111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Grove, T. Huby, Z. Stamataki, T. Vanwolleghem, P. Meuleman, M. Farquhar, A. Schwarz, M. Moreau, J. S. Owen, G. Leroux-Roels, et al. Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity J. Virol., April 1, 2007; 81(7): 3162 - 3169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Kapadia, H. Barth, T. Baumert, J. A. McKeating, and F. V. Chisari Initiation of Hepatitis C Virus Infection Is Dependent on Cholesterol and Cooperativity between CD81 and Scavenger Receptor B Type I J. Virol., January 1, 2007; 81(1): 374 - 383. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
